Key Events This Week
18 May: Stock opens at Rs.2,302.55, down 2.70%
21 May: New 52-week and all-time high at Rs.2,560
22 May: Hits record high of Rs.2,619.95
22 May: Week closes at Rs.2,528.85, up 6.86%
18 May 2026: Opening Week on a Weak Note
Fredun Pharmaceuticals began the week at Rs.2,302.55, declining 2.70% from the previous close. This drop contrasted with the Sensex’s smaller 0.35% decline to 35,114.86, indicating initial profit-taking or market caution. The stock traded on moderate volume of 16,548 shares, reflecting some investor hesitation amid broader market volatility.
19 May 2026: Recovery Gains Momentum
The stock rebounded sharply on 19 May, climbing 2.71% to Rs.2,365.00, outperforming the Sensex’s 0.25% gain. Volume declined to 9,267 shares, suggesting selective buying interest. This recovery marked the start of a sustained upward trend, supported by positive sentiment around the company’s fundamentals and technical positioning.
20 May 2026: Continued Uptrend with Steady Gains
Fredun Pharmaceuticals extended its rally on 20 May, rising 2.52% to Rs.2,424.65. The Sensex also advanced 0.28%, but the stock’s outperformance was notable. Trading volume moderated further to 7,219 shares. The stock’s price remained comfortably above key moving averages, signalling sustained bullish momentum.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
21 May 2026: New 52-Week and All-Time Highs
On 21 May, Fredun Pharmaceuticals surged 5.28% to close at Rs.2,552.75, hitting a new 52-week high of Rs.2,560 intraday and an all-time closing high of Rs.2,560.00. This represented a remarkable 10.7% gain over three consecutive sessions. The stock outperformed the Sensex, which rose only 0.12%, and its sector by 4.84%. Volume increased to 14,839 shares, reflecting strong buying interest.
The rally was underpinned by robust financial results, including a 56.70% year-on-year increase in quarterly net sales to Rs.160.93 crore and record operating profit before depreciation and interest of Rs.26.34 crore. Profit before tax excluding other income reached Rs.14.00 crore, the highest quarterly figure to date. Promoter shareholding rose by 1.11% to 44.17%, signalling confidence in the company’s prospects.
Technically, the stock traded above all key moving averages and showed bullish signals from MACD, Bollinger Bands, and KST indicators. The sustained momentum amid a volatile broader market highlighted Fredun Pharmaceuticals’ relative strength.
22 May 2026: Record High and Weekly Close
Fredun Pharmaceuticals continued its ascent on 22 May, reaching a new 52-week and all-time high intraday price of Rs.2,619.95. Despite a slight day decline of 0.94% to close at Rs.2,528.85, the stock outperformed the Sensex’s 0.21% gain. This marked the fourth consecutive day of gains, with a cumulative four-day return of 12.92%.
Volume stood at 9,719 shares, with delivery volumes showing strong participation. The stock’s valuation metrics remained premium, with a price-to-earnings ratio of 43x and a PEG ratio of 0.76x, reflecting earnings growth of 81.2% over the past year. Return on capital employed was a healthy 20.2%, though enterprise value to capital employed was relatively high at 4.91x.
Fredun Pharmaceuticals’ long-term returns remain exceptional, with a one-year gain of 258.51%, far outpacing the Sensex’s 6.70% decline. Year-to-date, the stock has surged 64.67%, while the Sensex fell 11.38%. The company’s consistent quarterly growth, rising promoter stake, and strong technical indicators underpin this sustained outperformance.
Curious about Fredun Pharmaceuticals Ltd from ? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-18 | Rs.2,302.55 | -2.70% | 35,114.86 | -0.35% |
| 2026-05-19 | Rs.2,365.00 | +2.71% | 35,201.48 | +0.25% |
| 2026-05-20 | Rs.2,424.65 | +2.52% | 35,299.20 | +0.28% |
| 2026-05-21 | Rs.2,552.75 | +5.28% | 35,340.31 | +0.12% |
| 2026-05-22 | Rs.2,528.85 | -0.94% | 35,413.94 | +0.21% |
Key Takeaways
Strong Financial Growth: Fredun Pharmaceuticals’ latest quarterly results demonstrated robust revenue growth of 56.70% and record operating profits, supporting the stock’s upward momentum.
Promoter Confidence: The increase in promoter shareholding by 1.11% to 44.17% reflects strong insider conviction in the company’s prospects.
Technical Strength: The stock’s consistent trading above key moving averages and bullish technical indicators such as MACD and Bollinger Bands underpin its sustained rally.
Valuation Considerations: While the stock trades at a premium valuation with a P/E of 43x and EV/CE of 4.91x, these metrics are supported by strong earnings growth and market-beating returns.
Market Outperformance: The stock’s 6.86% weekly gain significantly outpaced the Sensex’s 0.50% rise, highlighting its relative strength amid a cautious broader market.
Conclusion
Fredun Pharmaceuticals Ltd’s performance during the week of 18 to 22 May 2026 was marked by significant milestones, including new 52-week and all-time highs. Supported by strong financial results, rising promoter stake, and positive technical signals, the stock demonstrated resilience and outperformance relative to the broader market. Despite a premium valuation, the company’s robust earnings growth and consistent operational improvements justify investor interest. The stock’s trajectory underscores its position as a noteworthy micro-cap player within the Pharmaceuticals & Biotechnology sector, delivering substantial returns across multiple timeframes.
Only Rs. 20,999 - Get MojoOne + Stock of the Week for 3 Years Get 71% Off →